An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis

Koike, Yuta; Fujiki, Yumi; Higuchi, Maho; Fukuchi, Reika; Kuwatsuka, Sayaka; Murota, Hiroyuki

doi:10.1016/j.jdcr.2018.11.016

Cited by 21 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case report on a patient with CHB treated with ixekizumab and entecavir simultaneously did not develop HBVr after 18 mo of treatment[ 53 ]. Another report showed that a patient with resolved HBV did not experience HBVr during follow-up (Table 2 )[ 54 ].…”

Section: Il-17 Inhibitorsmentioning

confidence: 99%

Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics

Akiyama¹,

Cotter²,

Sakuraba³

2021

WJG

View full text Add to dashboard Cite

Hepatitis B virus reactivation (HBVr) can occur in patients treated with immunosuppressive medications. Risk stratification for HBVr based on hepatitis B virus (HBV) serology and viral load is an important strategy to determine appropriate HBV monitoring and antiviral prophylaxis use. Recent advances in the understanding of pathophysiology of autoimmune diseases have led the development of cytokine-targeted therapies. Tumor necrosis factor (TNF)-α inhibitors have been widely used for patients with inflammatory bowel disease, psoriasis, and rheumatic diseases. Further, the clinical benefits of interleukin (IL)-12/23, IL-17, or Janus kinases inhibitors have been demonstrated in these patients. It is well known that TNF-α inhibitor use can lead to HBVr, however, the risk of HBVr in patients undergoing non-TNF-targeted biologics have not been fully understood. In this review, we discuss the risk of HBVr in patients treated with non-TNF-targeted biologics, and immunological mechanisms of these medications causing HBVr.

show abstract

Section: Il-17 Inhibitorsmentioning

confidence: 99%

Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics

Akiyama¹,

Cotter²,

Sakuraba³

2021

WJG

View full text Add to dashboard Cite

show abstract

“…This case and the literature findings indicate that IL17A blockage may help treat various autoimmune and inflammatory conditions that lead to renal failure [ 28 ].…”

Section: Discussionmentioning

confidence: 95%

Ixekizumab May Improve Renal Function in Psoriasis

Amoruso¹,

Nisticò

Iannone

et al. 2021

Healthcare

View full text Add to dashboard Cite

Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case report: In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions. Conclusions: IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions.

show abstract

“…Cases of chronic or resolved HBV infection in patients undergoing secukinumab therapy have been reported [ 86 , 87 ], but none were found to have hepatitis or virus reactivation. A good safety profile was shown also for ixekizumab: 2 reports in the literature (one with active HBV infection and concurrently treated with entecavir and one with both markers of past HBV infection and anti-HCV positivity and no signs of reactivation) suggest the drug as safe in this setting [ 88 , 89 ]. No cases of reactivation of HBV have been reported in randomized controlled trials of brodalumab and its safety has not been yet established in HBV or HCV patients by real-world data [ 84 ].…”

Section: Discussionmentioning

confidence: 99%

Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a chronic immune-mediated skin and joint disease, with a plethora of comorbidities, characterized by a certain genetic predisposition, and a complex pathogenesis based on the IL-23/IL-17 pathway. There is no doubt that the patients affected by psoriasis are more susceptible to infections as well as that the risk of infection is higher in psoriatic subjects than in the general population. The advent of biotechnological agents on the therapeutic arsenal actually available for the treatment of moderate-to-severe patients, given the fact that the severity of the disease is a predictor of the level of infectious risk, has raised the question of whether these ‘new’ drugs could be considered a safer option and how they can be used in selected cases. Old and newer strategies in cases of chronic infectious conditions are reviewed under the light of clinical trials and other studies present in literature.

show abstract

An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis

Cited by 21 publications

References 8 publications

Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics

Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics

Ixekizumab May Improve Renal Function in Psoriasis

Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease

Contact Info

Product

Resources

About